Finding new treatments to prevent and manage glaucoma
Discovery of novel disease modifying therapy for the prevention and treatment of glaucoma
['FUNDING_R21'] · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · NIH-10947709
This study is looking for new ways to help people with glaucoma by finding treatments that not only lower eye pressure but also protect against the damage the disease causes, so you can keep your vision for longer.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NORTH TEXAS HLTH SCI CTR (nih funded) |
| Locations | 1 site (FORT WORTH, UNITED STATES) |
| Trial ID | NIH-10947709 on ClinicalTrials.gov |
What this research studies
This research aims to discover innovative therapies that can modify the disease process of glaucoma, which is a leading cause of blindness. Current treatments primarily focus on lowering eye pressure but do not address the underlying damage caused by the disease. The researchers are investigating the molecular mechanisms that lead to this damage and are using advanced computational methods to identify new agents that can disrupt harmful protein interactions involved in glaucoma. By targeting these pathways, the goal is to develop treatments that not only slow down vision loss but also prevent it.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma, particularly those who are experiencing progressive vision loss despite current treatments.
Not a fit: Patients who have not been diagnosed with glaucoma or those with advanced glaucoma who have already lost significant vision may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the quality of life for glaucoma patients by preserving their vision.
How similar studies have performed: While there have been advancements in glaucoma treatment, this approach targeting specific molecular pathways is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
FORT WORTH, UNITED STATES
- UNIVERSITY OF NORTH TEXAS HLTH SCI CTR — FORT WORTH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CLARK, ABBOT FREDERICK — UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
- Study coordinator: CLARK, ABBOT FREDERICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.